1,721,224 research outputs found
La progettazione organizzativa nelle aziende ospedaliere: criteri e strumenti per la dipartimentalizzazione
No full textIl decoupling nelle organizzazioni sanitarie: Il caso dei dipartimenti ospedalieri italiani
No full textIl decoupling nelle organizzazioni sanitarie: Il caso dei dipartimenti ospedalieri italian
Cost-effectiveness analysis of Daclatasvir/Sofosbuvir for the treatment of the HCV patients failed after the first line with second generation of DAAs in Italy .
No full textThe social cost of major depression. A systematic review
Full text linkMajor depression (MD) is a major cause of disability and a significant public health problem due to strong physical and
mental impairment, possible complications for patients (including suicides), serious social and working problems to the
patient and his/her family. We provide an overview of the social cost of Major depression worldwide. We conducted a
systematic literature review. Two search engines were queried. Screening of records and summary of evidence was
performed by two researchers blindly. The review was conducted in accordance with the standards of the PRISMA
guidelines.
Twenty studies met the inclusion criteria. Despite the heterogeneity in terms of population, setting and estimation
techniques, the studies showed that the largest share of the burden of disease is represented by indirect costs. Among
direct healthcare costs, inpatient care represents the most significant item, followed by outpatient care. The average total
direct cost of depression ranges between €508 and €24 069, depending on the jurisdiction where the analysis was run and
the range of cost items included. Indirect costs range between €1963 and €27 364.
Evidence on the cost of MD in some countries is currently lacking. A deeper understanding of the drivers of the economic
burden of disease is a crucial starting point for studies concerned with the cost-effectiveness of new treatment strategies
Network Prominence and Innovation: An Empirical Analysis of Corporate-backed Biotech Spin-offs
No full textWith increasing dynamics and complexity in the biotechnology industry,
pharmaceutical companies are forced to broaden the scope of their R&D
operations, increasingly relying on external sources of new knowledge. In this
context, corporate venturing emerges as an interesting means to exploit new
entrepreneurial sources of innovation. By investing in academic spin-offs, and
thereby establishing relationships with academic R&D actors, knowledge
dispersed in scientific and academic networks can be accessed by the pharmaceutical companies. In this way, equity investments in academic spinoffs present a potential to improve the investors’ innovation performance. Based
on a study of 97 corporate-backed academic spin-offs in the biotech field, this
paper investigates how structural characteristics of these spin-offs’ R&D
networks influence the innovativeness of big pharmaceutical companies that
provide venture capital to the spin-offs. In particular, the effect of a spin-off ’s
prominence in its knowledge network is analyzed, using different network centrality measures. The results obtained show that investments in academic
spin-offs holding prominent positions in their R&D networks significantly
contribute to the innovativeness of their investors, in terms of the number of patents resulting from these collaborations
- …
